Cyclic adenosine 3',5'-monophosphate-binding proteins in human ovarian cancer: correlations with clinicopathological features

• Published in: Clinical cancer research Vol. 2; no. 1; pp. 201 - 206
• Main Authors: SIMPSON, B. J. B, RAMAGE, A. D, HULME, M. J, BURNS, D. J, KATSAROS, D, LANGDON, S. P, MILLER, W. R
• Format: Journal Article
• Language: English
• Published: Philadelphia, PA American Association for Cancer Research 01.01.1996
• Subjects: Biological and medical sciences; Carrier Proteins; Cyclic AMP Receptor Protein - analysis; Cyclic AMP-Dependent Protein Kinases - metabolism; Female; Female genital diseases; Gynecology. Andrology. Obstetrics; Humans; Medical sciences; Neoplasm Proteins - analysis; Ovarian Neoplasms - chemistry; Ovarian Neoplasms - mortality; Ovarian Neoplasms - pathology; Survival Rate; Tumors; Human; Ovarian diseases; Ovary; Binding protein; Tissue; Histopathology; Prognosis; Cyclic AMP; Malignant tumor; Female genital diseases
• ISSN: 1078-0432; 1557-3265

The regulatory subunits of protein kinase A, or cyclic AMP-binding proteins, were measured in a series of 107 human ovarian tumors (89 malignant, 7 borderline, and 11 benign tumors) and related to tumor clinicopathological features and patient survival. Total cyclic AMP-binding protein levels were not significantly different between malignant tumors and either borderline or benign tumors. However, serous tumors showed significantly higher levels of total cyclic AMP-binding proteins than other malignant tumors (P = 0.007). Poorly differentiated tumors also possessed significantly higher levels of binding proteins as compared with well/moderately differentiated tumors (P < 0.01). Retrospective analysis of follow-up data also revealed a significant trend for patients with high tumor cyclic AMP-binding proteins to have poorer survival (P = 0.03). Individual binding proteins were identified by photoaffinity labeling, and the RI (Mr 48,000) protein was expressed as a percentage of total cyclic AMP-binding proteins detected. The percentage of the RI protein was not significantly different among malignant, borderline, or benign pathologies and was not associated with tumor stage, differentiation, or debulk status. The percentage of RI was significantly increased in serous tumors compared to other common epithelial malignancies (P = 0.01). In malignant tumors there was a significant positive correlation between the percentage of the RI protein and total cyclic AMP-binding proteins (P = 0.01). These data indicate that high tumor levels of cyclic AMP-binding proteins are associated with serous histology, poor differentiation, and poor patient survival.